Payment overview · 2025
General Payments
$284.79
4 reported records · 4 companies
Healthcare provider profile · identity verified
Daniel Joseph Chagin, MD
Allopathic & Osteopathic Physicians|Family Medicine · CLEVELAND, OH · NPI 1407863152
Verified facts
What the public records show
CMS Open Payments records show Daniel Joseph Chagin, MD received $284.79 in general payments during 2025 across 4 reported records.
Novo Nordisk Inc accounted for 42.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.83 | 42.8% | 1 | 2025 |
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $90.00 | 31.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $56.16 | 19.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.80 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $284.79 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| Altis Normalized: altis |
Device | COLOPLAST CORP | $90.00 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $56.16 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 506 | 118 |
| Lisinopril | Lisinopril | 302 | 86 |
| Omeprazole | Omeprazole | 249 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 244 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 79 |
| Furosemide | Furosemide | 229 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 62 |
| Gabapentin | Gabapentin | 223 | 42 |
| Alprazolam | Alprazolam | 222 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 42 |
| Simvastatin | Simvastatin | 166 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 35 |
| Jardiance | Empagliflozin | 151 | 25 |
| Losartan Potassium | Losartan Potassium | 145 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 28 |
| Sertraline Hcl | Sertraline Hcl | 127 | 29 |
| Metformin Hcl | Metformin Hcl | 123 | 28 |
| Ezetimibe | Ezetimibe | 121 | 34 |
| Ozempic | Semaglutide | 105 | 27 |
| Xarelto | Rivaroxaban | 103 | 22 |
| Warfarin Sodium | Warfarin Sodium | 101 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 13 |
| Trazodone Hcl | Trazodone Hcl | 93 | 27 |
| Meloxicam | Meloxicam | 88 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 18 |
| Tramadol Hcl | Tramadol Hcl | 79 | 24 |
| Ibuprofen | Ibuprofen | 78 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 18 |
| Potassium Chloride | Potassium Chloride | 71 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 67 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 22 |
| Prednisone | Prednisone | 66 | 15 |
| Pregabalin | Pregabalin | 65 | suppressed |
| Allopurinol | Allopurinol | 64 | 15 |
| Atenolol | Atenolol | 64 | 18 |
| Buspirone Hcl | Buspirone Hcl | 64 | 16 |
| Eliquis | Apixaban | 63 | 15 |
| Famotidine | Famotidine | 62 | 19 |
| Glimepiride | Glimepiride | 58 | 17 |
| Montelukast Sodium | Montelukast Sodium | 56 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 55 | 18 |
| Sucralfate | Sucralfate | 54 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 16 |
| Metformin Hcl Er | Metformin Hcl | 53 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 11 |
| Methylprednisolone | Methylprednisolone | 49 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 45 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 45 | 12 |
| Amoxicillin | Amoxicillin | 43 | 35 |
| Finasteride | Finasteride | 42 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Lorazepam | Lorazepam | 36 | 11 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 17 |
| Nystatin | Nystatin | 35 | 20 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 22 |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 11 |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 12 |
| Ondansetron Odt | Ondansetron | 31 | 11 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Clarithromycin | Clarithromycin | 28 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 22 | 18 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 15 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Dupixent Syringe | Dupilumab | 12 | suppressed |
| Klonopin | Clonazepam | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $284.79 · 4 records | Novo Nordisk Inc | Altis, FREESTYLE LIBRE 3, Ozempic, XIFAXAN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error